The Merlini, Waldenström, Jayakar staging system revisited

Area of Science:

• Oncology
• Hematology
• Biostatistics

Background:

• Current multiple myeloma staging systems require refinement to incorporate novel prognostic factors.
• Serum beta-2 microglobulin (S-beta-2M) is a recognized prognostic marker in multiple myeloma.

Purpose of the Study:

• To evaluate the prognostic significance of various factors, including S-beta-2M, to enhance the Merlini, Waldenström, Jayakar (MWJ) staging system.
• To identify key prognostic indicators in a retrospective cohort of multiple myeloma patients.

Main Methods:

• Cox regression hazards analysis applied to 345 retrospective multiple myeloma patients.
• Evaluation of factors including serum creatinine, albumin, bone marrow plasma cells, and S-beta-2M.
• Assessment of S-beta-2M's prognostic value as both a continuous and binary variable.

Main Results:

• Serum creatinine, albumin, and bone marrow plasma cells explained 94% of the prognostic variance in the overall cohort.
• S-beta-2M, serum creatinine, and bone marrow plasma cells were significant predictors when S-beta-2M was available (92% variance explained).
• An S-beta-2M level of 4 mg/l was the optimal discriminatory threshold; its prognostic impact was reduced when used dichotomously. Early-stage patients with S-beta-2M < 4 mg/l had a median survival of 70 months versus 40 months for those with S-beta-2M > 4 mg/l. S-beta-2M provided no additional prognostic information in stage 3 patients.

Conclusions:

• Serum beta-2 microglobulin, serum creatinine, and bone marrow plasma cell percentage are powerful prognostic indicators in multiple myeloma.
• Incorporating S-beta-2M levels, particularly as a continuous variable, can refine prognostic assessments for early-stage multiple myeloma.
• The MWJ staging system can be improved by integrating S-beta-2M, especially for patients with stages 1 and 2 disease.